Professionisti del settore sanitario

Resolute Integrity DES

Zotarolimus-Eluting Coronary Stent System

Innovative design, powerful performance

A Revolutionary Stent Platform with Continuous Sinusoid Technology

The Resolute Integrity™ drug-eluting coronary stent with Continuous Sinusoid Technology starts with a single strand of wire formed into a sinusoid, wrapped in a helical pattern, and laser fused.

Two stent designs:

  • 2.25-2.75 mm overexpands to 3.75 mm MSID
  • 3.0-4.0 mm overexpands to 4.75 mm MSID

Proven in Bifurcation Lesions1

Unique stent platform is proven in bifurcation lesions and offers:

  • Smooth round struts for easy wire and balloon sidebranch access
  • Open cell design for large sidebranches

Safety Assured

Exceptional safety with low 1.2% stent thrombosis at 5 years showing sustained long-term safety.2

Product Details

A paradigm shift in stent design and manufacturing: Continuous Sinusoid Technology

Continuous Sinusoid Technology

Flexible stent platform for outstanding flexibility and conformability

Sinusoid- formed wire

helical wrap


Superior deliverability, flexibility, and trackability3

Image of Resolute Onyx DES

Resolute Integrity Stent Struts

zortarlimus drug image

Resolute Integrity Zotarolimus Drug

biolinx polymer image

Innovative BioLinx™ polymer

mircotrac delivery system

Resolute Integrity Microtrac Delivery System

Advantages in Coronary Bifurcations

  • Smooth round struts for easy wire and balloon sidebranch access
  • Open cell design expandable to more than 3.8 mm for large sidebranches4
  • Stent overexpansion to 4.75 mm for proximal vessel optimization6
  • Excellent flexibility and conformability for superior strut apposition in provisional bifurcation treatment5
Superior deliverability, flexibility, and trackability

For many stent designs, complex irregular cell shape may obstruct wire or catheter 

Superior deliverability, flexibility, and trackability

Product Specifications


Kornowski, PCR 2013.  Post-hoc pooled analysis of RESOLUTE All Comer and RESOLUTE International. Study was not powered or prespecified for this endpoint. 


Yeh et al. 5-year safety and efficacy of Resolute zotarolimus-eluting stent, JACC Cardiovascular Interventions. 2017;10:247–254.


Compared with Xience Prime™* Promus Element™*. Data on file at Medtronic. These tests are not indicative of clinical performance.


Bench test data on file at Medtronic, Inc. Image of cell open area is for illustrative purposes only. 3.8 mm side branch expansion applicable to 3.0-4.0-mm stent sizes. May not be indicative of clinical performance.


Mortier, PCR 2013. These tests may not be indicative of clinical performance.


4.75 mm overexpansion applicable to 3.0-4.0 mm stent sizes.